We retrospectively analysed the factors that influenced rate of haemopoietic recovery (HR) in 243 patients after transplantation with chemotherapy-mobilised autologous peripheral blood progenitor cells (PBPC). Approximately half the patients also received haemopoietic growth factors (HGF) for mobilisation. Conditioning for transplantation was with either chemotherapy alone or chemotherapy plus total body irradiation (TBI). Median time to recovery of granulocytes у0.5 ؋ 10 9 /l was 13 days (range 7-93 days) and of platelets у50 ؋ 10 9 /l 14 days (7-440). Speed of HR was greater, both for neutrophils and platelets for patients who received more rather than less CFU-GM than our median value of 18.9 ؋ 10 4 /kg (P Ͻ 0.0001 in both instances) and more rather than less CD34-positive cells than our median value of 8.8 ؋ 10 6 /kg (P Ͻ 0.0001 and P Ͻ 0.0005, respectively). For granulocyte recovery, in the multivariate analysis the dose of infused CFU-GM (P = 0.05) and the use of HGF for both mobilisation and posttransplantation (P Ͻ 0.0014) were significant positive factors. For platelet recovery in the multivariate analysis the dose of infused CFU-GM (P Ͻ 0.0016) was a positive factor. The use of busulphan and of TBI were significant adverse factors for rate of platelet recovery (P = 0.005 and 0.0004, respectively). When compared with non-HGF-mobilised PBPC, HGF-mobilised PBPC reduced the number of days of hospitalisation (28 vs 24, P = 0.0001) and of treatment with intravenous antibiotics (15 vs 11, P = 0.0004). These findings emphasise the importance of cell dose in accelerating haemopoietic recovery after autologous blood stem cell transplantation.
Autologous peripheral blood progenitor cell transplantation (APBPCT), first performed in the mid-1980s 1,2 is now a commonplace medical procedure for treatment of a range of haematological malignancies 3, 4 and increasingly, for solid tumours. 5 It was developed after autologous bone marrow transplantation (AuBMT) was shown to be of value for treatment of leukaemias, lymphomas and other neoplastic diseases. 3, 6 While the original hypothetical basis for its introduction -that PBPCs were less likely to be contaminated with malignant cells than were bone marrow (BM) stem cells -has not been substantiated, [7] [8] [9] the procedure has gained favour because it leads to accelerated HR when compared with AuBMT. Thus it has proved to be safer 10 and cheaper 11, 12 than AuBMT and world-wide APBPCT is now performed more frequently than AuBMT. 13 Previous studies have shown that the rate of HR, which is the major factor influencing the safety of APBPCT, is linked to a variety of patient, disease and treatment-related variables but is especially enhanced by use of HGF for PBPC mobilisation.
14 Knowledge of the variables is clearly important in aiding selection of patients for safe transplantation and in determining timing and methodology in individuals. We have reported previously the results in our first 118 patients with haematological malignancies treated with APBPCT between 1984 and 1993; 15 in the subsequent three years we have more than doubled our experience and we now report the findings in the larger series of 243 consecutive patients treated at a single institution. In carrying out this retrospective exploratory analysis, we aimed particularly to identify factors that promoted rapid HR, as a guide to safer transplantation.
Materials and methods
All patients in our institution who underwent APBPCT between 1984 and 1996 inclusive are included in this report. Methods of PBPC collection, 15 cryopreservation 16 and reinfusion 17 have been previously reported.
Laboratory methods
Enumeration of CD34-positive cells was performed by flow cytometric analysis on an Ortho Cytotron Absolute instrument using Immunocount II acquisition software. 3 was separately determined on a Cell Dyn 3500R counter (Abbott, Santa Clara, CA, USA). The absolute number of CD34-positive cells/mm 3 was then calculated using the formula (%CD34-positive cells ϫ number of WBC/mm 3 )/100. Enumeration of CFU-GM was carried out on fresh apheresis material after isolation of WBC using modified fluid gelatine (Plasmion; Rhône-Poulenc Rorer, Neuilly-surSeine, France) and washing in Hank's solution; for frozen samples, mononuclear cells were thawed in AB plasma and isolated on a gradient. Cells were then seeded in Pike's agar culture medium supplemented with placenta-conditioned medium at two concentrations, 1 and 5 ϫ 10 5 /ml. CFU-GM were then read after 10 days incubation at 37°C in a humidified atmosphere containing 5% carbon dioxide.
Statistical methods
This was a retrospective, uncontrolled, exploratory analysis. The comparison of patients' characteristics was done using the 2 and Fisher exact tests for discontinuous variables, and the Wilcoxon test for continuous variables. HR was assessed by the number of days following APBPCT to reach a WBC count of 1.0, a granulocyte count of 0.5 or a platelet count of 20 or 50 ϫ 10 9 /l, using the Kaplan-Meier method. However, as the findings for recovery of total WBC and of granulocytes were virtually identical, as were those of the two levels of platelets, only those for granulocytes and for platelets of 50 will be presented in detail. The number of days of fever (temperature у38.0°C), hospitalisation, use of intravenous (i.v.) antibiotics and use of i.v. amphotericin were also calculated. The following prognostic factors were analysed: sex (male vs female); age; diagnosis; interval from diagnosis to transplantation (Ͻ7.5 months (median) vs у7.5 months); conditioning regimens (TBI-containing vs busulphan-containing regimens vs others (BEAM/BEAC/CBV)); type of mobilisation (type of chemotherapy, and chemotherapy alone vs chemotherapy plus HGF); remission status of disease at time of transplant (complete remission (CR) vs others; CR1 vs CR2 in acute leukaemia); dose of infused nucleated cells, dose of infused CD34-positive cells and dose of infused CFU-GM (analysed as discontinuous variables, divided at the median); use of HGF (none vs mobilisation only vs both mobilisation plus post-transplant; because of small numbers patients who received post-transplant HGF only were not separately analysed).
The influence of these prognostic factors on HR was performed using the log-rank test for univariate analyses, and the Cox regression model for multivariate analyses. For univariate covariates to qualify for inclusion in the multivariate analysis required a P value of Ͻ0.05. P values are presented and, for certain analyses, relative risk (rr) with 95% confidence intervals.
Results

Demographics and collection procedure
Between 1984 and 1996 inclusive we treated 243 patients (157 male). Their median age at diagnosis was 45.8 years (range 6-68), their age at transplantation was 47.5 years (11-70) and the interval from diagnosis to APBPCT 7.5 months (2-214). Details of their diagnoses and methods of PBPC mobilisation are shown in Table 1 . The median number of leucapheresis procedures was six (range 1-8). As can be seen, mobilisation was with chemotherapy in all except four cases, and was supplemented by HGF in approximately half. The chemotherapy was high-dose cyclophosphamide (7 g/m 2 ) for lymphoma and multiple myeloma (MM), 18, 19 and mostly daunorubicin with cytarabine for acute leukaemia. 20 The specific HGF used were granulocyte colony-stimulating factor (G-CSF) in 96 cases, granulocyte-macrophage colony-stimulating factor (GM-CSF) in 25 cases and either GM-CSF or placebo in a randomised, controlled study in 28 MM patients. 19 Growth factors were administered at a dosage of 5 g/kg per day from the day after completion of chemotherapy until the day of the final leucapheresis. The four lymphoma patients who were given G-CSF only, without chemotherapy, received 10 g/kg per day for 6 days.
Transplantation
All patients received single transplants. Conditioning regimens were classified as busulphan-containing (n = 36), TBI-containing (n = 128) and others (n = 79). Busulphan (4 mg/kg per day for 4 days) was mostly combined with melphalan (n = 34); busulphan-containing regimens were used only for acute leukaemia. TBI (10-13.5 Gy) was always combined with chemotherapy, namely melphalan alone (n = 80), cyclophosphamide alone (n = 19), cyclophosphamide-containing combinations (n = 21) or cytarabinecontaining combinations (n = 8) and was used for acute leukaemia (n = 30), MM (n = 81) and some lymphomas (n = 17). The chemotherapy for lymphoma was usually BEAC 21 (n = 37) but on some occasions was BEAM 22 (n = 9) or CBV 23 (n = 14). One patient with acute leukaemia and four with MM received melphalan alone because of contraindications to TBI. A variety of regimens was used for the solid tumours.
The number of cells infused was as follows, given as median (range): nucleated cells 7.0 (1.7-95. /l); all but four of them had also received HGF for pre-harvest mobilisation.
The time from transplantation to haemopoietic recovery and related variables is shown in Table 2 . There were four early deaths before haemopoietic recovery: one on day 0 from cardiac arrest, one on day two from adult respiratory distress syndrome, one on day six from cardiac tamponade associated with thrombocytopenia, and one on day 10 probably from haemorrhage. Three patients with engraftment failure were given second grafts without further conditioning on days 23, 34 and 51; they comprised one patient with MM, a second patient with MM treated on the placebo-HGF trial, and one patient with AML, respectively.
Influence of use of HGF for harvesting
Comparison was made between patients who received and who did not receive HGF (in addition to chemotherapy) for harvesting and the results are shown in Tables 1 and 3 . This was not a controlled study, and the two groups differed significantly in terms of their diagnoses (Table 1) (P = 0.0017), ages, and the numbers of cells reinfused. Following transplantation, patients who received cells mobilised with HGF had a shorter period of hospitalisation and less use of antibacterial antibiotics (Table 3) .
Factors influencing granulocyte recovery
For speed of granulocyte recovery the following factors were found to be significant variables in the univariate analysis: diagnosis (P Ͻ 0.015) (solid tumours better than lymphomas better than other diagnoses), dose of infused nucleated cells (P Ͻ 0.05), dose of infused CD34-positive cells (P Ͻ 0.0001), dose of infused CFU-GM (P Ͻ 0.0001), and use of HGF (P Ͻ 0.0001). The sex or age of the patient, remission status of the disease at time of transplantation, interval from diagnosis to transplantation, and type of conditioning regimen were not significant factors. In the multivariate analysis (Table 4) only the dose of infused CFU-GM ( Figure 1 ) and the use of HGF both for mobilisation and post-transplantation ( Figure 2 ) were significant factors. The use of HGF for mobilisation only was not a significant factor in the multivariate analysis. There was a trend favouring the number of infused CD34-positive cells.
Factors influencing platelet recovery
For speed of platelet recovery the following factors were found to be significant variables in the univariate analysis: chemotherapy used before harvest (P Ͻ 0.0001), dose of infused nucleated cells (P Ͻ 0.05), dose of infused CD34-positive cells (P Ͻ 0.0005), dose of infused CFU-GM (P Ͻ 0.0001), conditioning regimen (P Ͻ 0.0001) and HGF used for mobilisation (P Ͻ 0.005). HGF given after transplantation as well as for harvesting conferred no advantage over use of HGF for harvesting only. A diagnosis of acute leukaemia was adverse compared with all other diagnoses (P Ͻ 0.0005) (Figure 3 ), but whether patients with AML were in CR1 or CR2 was not a significant factor. However, platelet recovery was slower in patients with a diagnosis of AML compared with ALL (P = 0.0001). There was a trend in favour of a shorter interval from diagnosis to transplantation when analysed as a discontinuous variable (P = 0.06); as a dichotomised variable we found that patients who were transplanted after у7.5 months (median) had slower recovery of platelet counts than those transplanted after a shorter interval (P = 0.0096 for probability of platelet recovery to у20 ϫ 10 9 /l). The sex or age of the patient and the remission status of the disease at the time of transplantation were not significant factors.
In the multivariate analysis ( Table 5 ) the dose of infused CFU-GM (Figure 4 ) was the only significant positive factor. Busulphan (P = 0.009) and TBI (P = 0.0002) impacted adversely on the rate of platelet recovery ( Figure 5 ) but not granulocyte recovery.
Subgroup analyses by conditioning regimen and diagnosis were performed to further examine the relationship between cell dose and platelet recovery. We found no statistically significant relationship between cell dose and speed of platelet recovery in the busulphan-conditioned subgroup either by CD34-positive cell numbers (P = 0.29) or CFU-GM numbers (P = 0.15), or in the acute leukaemia subgroup when analysed by CD34-positive cell dose (P = 0.19). However, the speed of platelet recovery in 766 This comparative analysis of the effects of HGF excludes the 28 MM patients who were part of a blinded study of HGF, as listed in Table 1 .
Table 4
Factors affecting neutrophil recovery to у0.5 ϫ 10 Days since PBPCT CFU-GM dose <18.9 × 104/kg CFU-GM dose у18.9 × 104/kg Probability of PMN у 500 P < 0.0001 Figure 1 Rate of granulocyte recovery according to CFU-GM dose, showing that patients who were given у18.9 ϫ 10 4 /kg CFU-GM (median) had a speedier recovery (P Ͻ 0.0001).
patients with acute leukaemia was faster in those who received higher numbers of CFU-GM (P = 0.027) and we noted that the cumulative probability of achieving platelet recovery to 50 ϫ 10 9 /l by day 180 was 75 Ϯ 18% (95% CI) for acute leukaemia patients given a CFU-GM dose below our median compared with 90 Ϯ 12% for those Other diagnoses n = 180
Probability of platelets у 50000 Figure 3 Rate of platelet recovery according to diagnosis (leukaemia vs others) indicating a slower rate in patients with acute leukaemia (P = 0.0005).
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Table 5
Factors affecting platelet recovery to у50 ϫ 10 9 /l: multivariate analysis Probability of platelets у 50000
Figure 4
Rate of platelet recovery according to CFU-GM dose, showing that patients who were given у18.9 ϫ 10 4 /kg CFU-GM (median) had a speedier recovery (P Ͻ 0.0001). Others n = 79
Others/TBI P = 0.0002 TBI/Busulphan P = 0.009 Others/Busulphan P < 0.0001
Probability of platelets у 50000 Figure 5 Relationship between conditioning regimen and probability of platelet recovery, indicating busulphan and TBI to be significant adverse factors (P Ͻ 0.0001 and P = 0.0002, respectively), with busulphan-containing regimens having a greater adverse impact than TBI (P = 0.009 for comparison between busulphan and TBI).
given a dose above the median. Further subanalysis of the speed of platelet recovery in the acute leukaemia patients according to whether or not busulphan was included in the conditioning regimen failed to identify an advantage for larger numbers of CD34-positive cells (P = 0.76) or of CFU-GM (P = 0.53) (such detailed subanalyses, though, may be unreliable due to the relatively small numbers in each group). Thus we were unable to identify a 'threshold' cell dose, below which platelet recovery was delayed or failed to occur altogether, even within narrowly defined subgroups.
Influence of epoch (time period)
Because the patients were transplanted over a period of more than a decade, during which time there were many changes in clinical practice, we have also analysed the influence of date of transplantation on HR. We compared the first half of the series (first epoch) with the second half in terms of HR. We found that epoch (ie date of transplant) was not a factor for WBC or granulocyte recovery (P = 0.11 and 0.82, respectively) but it was a significant factor in platelet recovery (P = 0.003).
Discussion
We have previously reported a smaller group of patients whose results are included in the present cohort. In that study 15 by multivariate analysis we found that the dose of CFU-GM infused was the only significant factor that favourably affected the rate of HR (P Ͻ 0.0001). However, patients with AML or those transplanted after busulphan or TBI conditioning regimens had a trend to slower engraftment (P Ͻ 0.08), findings confirmed and strengthened by the present results.
The importance of cell dose, whether measured by numbers of CFU-GM or CD34-positive cells, is reinforced by our study. We found that the speed of HR was greater, both for neutrophils and platelets, for patients who received more rather than less CFU-GM than our median value of 18.9 ϫ 10 4 /kg (P Ͻ 0.0001 in both instances) and more rather than less CD34-positive cells than our median value of 8.8 ϫ 10 6 /kg (P Ͻ 0.0001 and P Ͻ 0.0005, respectively). Sutherland et al 24 noted that patients who received Ͻ15 ϫ 10 4 colony-forming cells/kg had slower recovery. Bensinger et al 5 showed increased speed of engraftment with higher CD34-positive cell dose, but found a poor correlation between CD34-positive cell dose and CFU-GM dose. Janowska-Wieczorak et al 25 found that CD34 numbers correlated with speed of platelet recovery and that CFU-GM numbers correlated with speed of neutrophil recovery. The CD34-positive population includes the CFU-GM and other in vitro colony-forming cells. 26, 27 Disagreements as to the strength of the relationship between CD34-positive cells and CFU-GM may be largely historical and may relate to the lack, until now, of a standardised methodology. As technology improves and the reliability of the assay for CD34-positive cells increases, it is likely that it will largely replace that for CFU-GM in routine practice. 28 Although a dose-response effect of PBPCs is clear Weaver et al 29 found that the most powerful mediator of both platelet and neutrophil recovery was the CD34 content of the infused product and suggested that a CD34-positive cell dose of Ͼ5 ϫ 10 6 cells/kg was optimal for ensuring rapid HR. Bensinger et al 5 recommended 2.5 ϫ 10 6 /kg as being 'important' for rapid neutrophil recovery and Ͼ5 ϫ 10 6 for achievement of platelet transfusion independence. As only three patients in our series who survived 30 days after transplant failed to engraft, we were unable to identify a specific threshold below which engraftment did not occur. This finding is consistent with that of Somlo et al 31 who also were unable to define a clinically important threshold number of CD34-positive cells, and who achieved successful long-term haematopoietic recovery after reinfusion of as few as 0.45 ϫ 10 6 /kg CD34-positive cells. Despite this, our findings indicate that HR is more rapid, and thus safer, when greater numbers of cells are reinfused.
In comparison with autologous transplantation using BM stem cells, patients who are given HGF-mobilised PBPC have a shortened recovery time of granulocytes and platelets, as reported both in uncontrolled 10, 24, [32] [33] [34] [35] and controlled studies, the latter also showing a significant shortening of length of hospitalisation 36, 37 and less expense. 11, 12 However, there have been few studies of HGF-stimulated vs non-HGF-stimulated PBPC collections and even fewer of HGFstimulated peripheral blood vs HGF-stimulated BM collections. 38, 39 Although not a controlled study, ours is one of the few to compare HGF-with non-HGF-mobilised PBPC for APBPCT. Our findings do show that mobilisation with HGF confers significant benefits, with shortening of the period of hospitalisation and less use of antibiotics. We also found that reduction in time to platelet recovery correlated with use of HGF for stem cell mobilisation and collection, whereas reduction in time to neutrophil recovery correlated with post-transplant use of HGF. There was no additional benefit for platelet recovery with use of post-transplant HGF. These findings are consistent with those of others both for neutrophils 29, 40 and platelets. 41, 42 Indeed from the point of view of platelet recovery, one study showed that use of HGF post-transplantation was actually detrimental when the numbers of CD34-positive cells infused were low, namely Ͻ5 ϫ 10 6 /kg, 35 perhaps by forcing stem cells to differentiate along the myeloid rather than megakaryocyte pathway.
Extensive prior cytotoxic chemotherapy and irradiation have been reported to adversely affect the yield of CD34-positive cells 43 and to lead to delayed platelet recovery. 44 We were not able directly to measure the extent of prior chemotherapy or radiotherapy; however, we did find a trend to a slower recovery of platelets (P = 0.06) but not of granulocytes in patients whose diagnosis-to-transplantation interval was prolonged, a parameter which is probably a surrogate for extent of prior therapy. Similarly, Weaver et al 29 found that patients who required two mobilisation procedures vs one experienced slower platelet recovery; a requirement for additional collection procedures is also probably a surrogate for extent of prior chemotherapy. These findings reinforce the importance of collection of PBPC early in the disease to avoid exhaustion of haemopoietic capacity by cumulative toxicity. 43 In our previous study we identified preparative regimens containing busulphan or TBI as having an adverse impact on HR, 15 a finding we have now confirmed. Both regimens led to a slower rate of HR than patients who received our 'other' regimens (mainly BEAC, CBV or BEAM); the adverse effect of busulphan-containing regimens was more severe than that of TBI-containing regimens. Bensinger et al 5 reported that patients who received TBI preparation had a more rapid rate of engraftment than patients who received busulphan-containing regimens, a finding consistent with ours. Weaver et al 29 found that patients who received a high-dose regimen of cyclophosphamide, thiotepa and carboplatin had a more rapid platelet recovery than patients receiving different regimens. Others have also found that the rate of HR after PBPCT is dependent on both mobilising and transplant regimens. 45 It is not clear why this should be so. Although both TBI and busulphan-containing regimens are more intensely myeloablative than certain other regimens such as BEAM, 46 and although stimulation of PBPC growth by use of an irradiated stromal layer has been demonstrated in vitro, 47 it seems unlikely that the former factor would influence rate of recovery of infused autologous cells, nor that the latter could operate so decisively in such a brief time interval in vivo. In our series, patients were given busulphan-containing regimens only for acute leukaemia and TBI-containing regimens mostly for MM, suggesting the underlying diagnosis may be relevant; but although diagnosis was a significant factor in the univariate analysis for recovery of both granulocytes and platelets (P Ͻ 0.05 and P Ͻ 0.0001, respectively), it did not remain a significant independent variable in the multivariate analysis.
Because our study was retrospective and uncontrolled, the conclusions must be tentative. Nonetheless, it is of interest that the most important factors associated with acceleration of HR after APBPCT were identified as the use of HGF for mobilisation and the dose of infused cells, measured either by numbers of CFU-GM or CD34-positive cells. These findings emphasise the need to optimise preparative and harvesting techniques to enhance safety and minimise morbidity and costs of this valuable procedure.
